# RayzeBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rayzebio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.rayzebio.com
- Total disclosed funding: $419M
- Latest round: Series D (Aug 25, 2022)
- Investors on record: 22

## About

RayzeBio, Inc. is a biotechnology firm based in the US, focused on developing innovative precision radiopharmaceutical therapies to enhance cancer treatment outcomes through the use of actinium-based isotopes.Founded in 2020 and headquartered in San Diego, US, RayzeBio, Inc. specializes in precision radiopharmaceutical therapies. The company has raised a total of USD 72.724 mn, with its latest funding round, LP Direct, occurring on September 14, 2023, involving an investment from Bristol-Myers Squibb Company. RayzeBio was co-founded by Aaron Kantoff, Aron Knickerbocker, and Deborah Charych, with Ken Song serving as the CEO. The firm has conducted 8 deals to date.RayzeBio specializes in precision radiopharmaceutical therapies (RPTs), emphasizing the innovative use of actinium-225 (Ac225). Their offerings aim to transform cancer treatment by providing targeted therapies that utilize alpha-emitting isotopes, thus minimizing side effects associated with traditional treatments. The company's products are tailored to meet the needs of oncology professionals and patients, enhancing therapeutic outcomes and quality of life. RayzeBio actively serves healthcare providers and cancer treatment centers across North America and Europe, where demand for advanced cancer therapies is significant.RayzeBio generates revenue primarily from direct sales of its precision radiopharmaceutical therapies to hospitals and specialized cancer treatment facilities. The sales transactions are structured as B2B engagements, where healthcare providers purchase these specialized products. The company’s pricing reflects the complexity and innovation of its actinium-based therapies, ensuring clients obtain access to advanced cancer treatment solutions. In the EBITDA for 2022, RayzeBio reported an amount of USD -71.276 mn.In September 2023, RayzeBio, Inc. raised USD 311 mn in an IPO, selling 17.28 million shares at USD 18 per share on Nasdaq. The company plans to utilize this funding to expand its range of radiopharmaceuticals and accelerate multiple major value inflection points both clinically and operationally. RayzeBio is focused on launching new products and is pursuing expansion into additional geographic markets, although specific markets and timelines have not been disclosed.

## Funding rounds

- Series D, Aug 25, 2022, $160M — Sofinnova Investments, Wellington Management, Viking Global Investors, Laurion Capital Management, Ally Bridge Group, Sands Capital Alternatives, Soleus Capital
- Series C, Jun 15, 2021, $109M — OrbiMed Advisors, Versant Ventures, Alexandria Venture Investments, Vivo Capital, Viking Global Investors, Redmile Group, VenBio, Deerfield Management, Cormorant Asset Management, Acuta Capital Partners, Perceptive Advisors, LifeSci Partners, Samsara BioCapital, Logos Capital, Venrock Healthcare Capital Partners, TCG Crossover Management
- Series B, Dec 8, 2020, $105M — OrbiMed Advisors, Versant Ventures, Alexandria Venture Investments, Viking Global Investors, Redmile Group, VenBio, Cormorant Asset Management, LifeSci Partners, Samsara BioCapital, Logos Capital, Venrock Healthcare Capital Partners
- Series A, Oct 14, 2020, $45M — Versant Ventures, VenBio, Samsara BioCapital

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B, Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B, Series C, Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B, Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B, Series C
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series B, Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- Acuta Capital Partners (https://capitalatlas.ai/funds/acuta-capital-partners) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series D
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series D
- Laurion Capital Management — Series D
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series D
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series D
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series D